Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 11.08 -4.07% -0.47
OLMA closed down 4.07 percent on Monday, March 18, 2024, on 1.98 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -4.07%
Volume Surge Other -4.07%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 13 hours ago
1.5x Volume Pace about 17 hours ago
Down 5% about 17 hours ago
Down 3% about 17 hours ago
Fell Below Lower Bollinger Band about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Targeted Therapy Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

Is OLMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.7911
52 Week Low 3.0
Average Volume 812,010
200-Day Moving Average 11.76
50-Day Moving Average 13.14
20-Day Moving Average 13.21
10-Day Moving Average 12.71
Average True Range 1.15
RSI (14) 34.64
ADX 20.08
+DI 13.31
-DI 27.80
Chandelier Exit (Long, 3 ATRs) 12.10
Chandelier Exit (Short, 3 ATRs) 14.39
Upper Bollinger Bands 15.28
Lower Bollinger Band 11.14
Percent B (%b) -0.02
BandWidth 31.28
MACD Line -0.57
MACD Signal Line -0.25
MACD Histogram -0.3204
Fundamentals Value
Market Cap 610.48 Million
Num Shares 55.1 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -4.80
Price-to-Sales 0.00
Price-to-Book 3.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.17
Resistance 3 (R3) 12.25 11.96 11.99
Resistance 2 (R2) 11.96 11.68 11.92 11.93
Resistance 1 (R1) 11.52 11.51 11.38 11.44 11.87
Pivot Point 11.24 11.24 11.16 11.20 11.24
Support 1 (S1) 10.80 10.96 10.65 10.72 10.29
Support 2 (S2) 10.51 10.79 10.47 10.23
Support 3 (S3) 10.07 10.51 10.17
Support 4 (S4) 9.99